KR101483121B1 - Composition for prevention or treatment of hyperlipidemia - Google Patents

Abstract

An aspect of the present invention is to provide a herbal composition for preventing or treating hyperlipemia. In addition, in one aspect, the composition may contain one or more of the following six active ingredients: bruvulus extract, sea bream extract, interlingua extract, ginseng extract, ginseng extract,

Description

TECHNICAL FIELD The present invention relates to a composition for preventing or treating hyperlipidemia,

The techniques disclosed herein relate to compositions for the prevention or treatment of hyperlipidemia.

The risk of hyperlipidemia due to changes in dietary habits and lifestyle habits is very high, so adults and adolescents are increasing the problem of hyperlipemia, and hyperlipemia causes complications such as diabetes and hypertension. Complex drugs are emerging to increase the therapeutic effect of existing cardiovascular treatment drugs such as the statin family. Some hyperlipidemia medicines have side effects that cause side effects such as hyperlipidemia medicines are urgently needed. As with hypertension medicines, it is time to develop medicines and natural products that have few side effects as lifelong medicines.

Examples of therapeutic agents for hyperlipidemia include cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors. Statins, fibrates, and ACAT inhibitors are used as therapeutic agents. Among them, statin drugs are widely used. This drug acts as an HMG-CoA reductase inhibitor to inhibit the synthesis of cholesterol. It decreases the concentration of LDL-cholesterol in the blood, I will. It also increases HDL-cholesterol, but only slightly increases the effect, because it increases only about 5-10% of the original value. Since myopathy may occur rarely, it is necessary to measure blood creatine kinase (CK) levels if myalgia is present at the time of drug administration. Currently, there is no drug for treating cardiovascular diseases using the Chinese herbal medicines (which means medicines formulated according to Chinese medicine principles according to the Pharmaceutical Affairs Law).

Published Patent No. 10-2010-0089910

There is a need to develop drugs with less side effects and relatively similar efficacy than conventional antihyperlipidemic agents. In one aspect of the present invention, an object of the present invention is to provide a herbal preparation. In another aspect of the present invention, an object of the present invention is to provide a herbal medicine preparation for preventing or treating hyperlipidemia. In another aspect of the present invention, it is an object of the present invention to provide a drug product having a drug efficacy that is similar to that of a conventional chemical drug drug, while reducing side effects of the drug.

In one aspect, the present invention provides a composition for preventing or treating hyperlipidemia, which comprises at least one selected from the group consisting of Bursuisil extract, sea water extract, waxy extract, ginseng extract, ginseng extract, Or a composition for preventing or treating obesity.

A composition for preventing or treating hyperlipidemia, a composition for preventing or treating diabetes, a composition for prevention or treatment of obesity, a composition for preventing or treating hyperlipidemia, a composition for preventing or treating hyperlipidemia, Lt; / RTI >

In another aspect of the present invention, there is provided a composition for preventing or treating cancer, comprising the above composition, wherein the composition comprises at least one selected from the group consisting of balsucilis extract: seaweed extract: intergranular extract: persimmon extract: persimmon extract: 1.5 to 2: 2.6 to 3: 0.4 to 1: 1.4 to 2: 0.8 to 1: 1, a composition for preventing or treating diabetes, or a composition for preventing or treating obesity.

The present invention in one aspect provides a composition wherein the daily dose of active ingredient is from 0.001 to 1 g / kg, based on dry weight.

In another aspect, the active ingredient is in powder form.

In another aspect, the composition provides that it is a food composition, and in one aspect it is a pharmaceutical composition.

The present invention in one aspect provides a composition wherein said extract is an extract of ethanol or alcohol.

The composition for preventing or treating hyperlipidemia according to the present invention has an effect of preventing and treating hyperlipidemia in one aspect and has an effect equivalent to that of simvastatin, a chemical drug used as a therapeutic agent for hyperlipidemia. In addition, it exhibits liver detoxification efficacy in one aspect.

FIG. 1 is a graph showing blood TG content of a normal group, a negative control group, Examples 1 and 2, and a positive control group (using simvastatin).
FIG. 2 is a graph showing the blood TCHO content of the normal group, the negative control group, Examples 1 and 2, and the positive control group.
FIG. 3 is a graph showing blood HDL contents of normal group, negative control group, Examples 1 and 2, and positive control group.
FIG. 4 is a graph showing blood LDL levels of normal group, negative control group, Examples 1 and 2, and positive control group.
FIG. 5 is a graph showing the blood GOT content of normal group, negative control group, Examples 1 and 2, and positive control group.
FIG. 6 is a graph showing blood GPT levels of normal group, negative control group, Examples 1 and 2, and positive control group.
7 is a graph showing blood γ-GPT content in the normal group, negative control group, Examples 1 and 2, and positive control group.

An aspect of the present invention provides a herbal composition for preventing or treating hyperlipemia. Hyperlipidemia refers to a condition in which many lipid substances are present in the blood and accumulate in the blood vessel wall to cause inflammation, resulting in cardiovascular disease. Recently, abnormal blood lipid status is defined as dyslipidemia.

In one aspect, the composition for preventing or treating hyperlipidemia may comprise, as an active ingredient, at least one selected from the group consisting of Bacillus lupulus extract, sea bass extract, cloacae extract, ginseng extract, Cyperaceae extract,

The active ingredient may be contained in an amount of 0.01 to 99.9% by weight based on the total weight of the composition, 0.01 to 70.0% by weight in one aspect, and 0.1 to 50.0% by weight in another aspect.

The composition disclosed in the present invention is characterized in that it comprises, in one aspect, a balsucil extract: a marine extract: a marine extract: a ginseng extract: a zygomycut extract: a marine extract: 1-3: 1.5-4: 0.1-2: 0.5-3: 0.1-2: 2 in another aspect and 1.5 to 2: 2.6 to 3: 0.4 to 1: 1.4 to 2: 0.8 to 1: 0.5 to 1 in a weight ratio of about 1: 1.7: 2.8: 0.6: 1.7: 1.0: 0.8.

The verrucelan described herein is a fruit of a perennial vinegal herbaceous perennial plant of the surgeon. It grows about 5m in length and usually grows in the central southern part of Korea. Hanltari is used for edible, industrial and medicinal purposes. It is also known as gulu lugu, which is also known as gulu lugu. It is also called a vine plant. It is known as a herbaceous plant widely distributed in the habitats of Korea, China, and Mongolia, and starch in the ground is used to make starch. In the oriental medicine and folk medicine, it is used as medicines for the treatment of roots, fruits and seeds in diabetes, diuretic, paralysis, jaundice and tuberculosis. Hinattari belongs to Park, Park. For example, Park is the scientific name Cucurbitaceae, and the seminiferous name is Trichosanthes kirilowii Maxim.

The sea-white described herein is the rhizome of azalea, salt leek, or mountain leek, a perennial herb that belongs to the lily family. The length of the plant is 30-60cm. The scales are close to the spherical shape and the outside is covered with white membrane quality bark. Leaves are alternate, semicircular columnar, empty in the middle, 20 ~ 45cm in length, leaf tips are apical, and leaf covers the stem. The peduncle is single, and the inflorescence is full bloom. The lower part is ovate with bracts. The peduncle is 1 ~ 1.5cm long, the petals are 6 pieces, magenta or pale magenta, Is six, longer than petals, and has a spherical shape. The fruit is taro type. It grows mainly in grassy fields and fields. It is distributed in most parts of China. It is said to be a wild herb, called Soosan, which warms the body and is said to be effective in indigestion, neuralgia, and heartburn. For example, perennial herbs belonging to the lily family include Allium macrostemon Bunge and Allium bakeri Regel.

The guinea fescue described in this specification is a branch of a broiler tree of camphor tree. The thin bark is called cinnamon (cinnamon) and the young branches are called 桂枝. It is also used when there is diarrhea and vomiting because it warms the stomach (stomach stomach) because it warms the stomach (stomach stomach). It is also used when there is no menstrual irregularity, menstrual period or stomach pain and abdominal pain. It promotes the circulation of blood, and thus it is used for the treatment of old boils and skin ulcers that do not heal well. It is known that the wrists release sweating in the early stages of cold, releasing the skin, and relieving the pain of the limbs and the limbs. For example, the scientific name of camphor tree is Lauraceae, and the broiler tree has names such as Cinnamomum cassia Blume and Cinnamomi Ramulus.

The dansans described in this specification is a perennial plant which is native to the northwestern part of Gyeongbuk province, Gangwon province, and belongs to the family Lamiaceae and Baeam Chaesong. The stem is purple and grows about 60cm in length. Leaves are long ovate and wide elliptical. In June ~ July, blue purple flowers bloom at the end of stem. Its roots are used as medicinal materials, the skin is red, and the inside is purplish. Dansam is said to have excellent efficacy in ejaculation, bruising, neuralgia, arthritis, especially gynecological diseases and menstrual irregularities. For example, Dansam has the scientific name Salvia miltiorrhiza Bunge.

The flax seed described in the present specification is dried or cut into half of an immature fruit of a citrus fruit such as a pizza plant gate, a mandarin orange belonging to a mandarin orange tree, and a citrus fruit such as a summer mandarin orange, and the fruit skin is thick, Respectively. Dried whole ripe fruit is called 'crust', which is equivalent to the fruit in terms of efficacy. It contains mainly isosakuranin, naringin, citriforlioside and poncirin. It is also used as a food additive, wisdom, (Stomach), obesity (张 通), goddam (痰痰), news (小 食), in the agency (行 气 寬 中) Gastrointestinal dyspepsia, allergic constitution, stomach gas removal, uterine drainage and intestines are effective in incompetence. However, no antidiabetic activity has been reported. For example, the scientific name of the pizza plant is Angiospermae, the scientific name of the rhizome is Rutales, and the citrus and plant names are Poncirus trifoliata Rofinesque.

The cichlids described in this specification are native to China and grown as medicinal plants. It is 30 ~ 60㎝ in height. It is hollow and its branches are somewhat cracked. The flower blooms in August, and it is white and bisphosphate. In one room, roots and stems are effective for calm, pain, and tonic, and are used for headache, anemia, and women's diseases. It is a directional plant and it is put in the closet to prevent mite in the private. It means the palace of Sichuan in China. There is a saying that if you give water to the dying pine root, you will regenerate the tree. The main components of the celadon are rhizomes such as essential oils such as Cnidilide, Ligustilide, Neocnidilide, Butylphthalide, Sedanonic Acid Anhydride, 1 to 2% of senkeunolide A, B, C, D, E, G, H, It helps the smooth circulation of tile blood, eliminates the wind that has entered the body, and also has the effect of the tongue. It is applied to symptoms such as dysmenorrhea caused by tachycardia circulation disorder, unusual physiology, abdominal pain, pain in the side, bruises, and headache. Astragalus is a medication that stimulates the blood circulation and helps the movement of energy to relieve pain. It has analgesic, sedation, increased coronary blood flow, anti-ulcer, hypotensive, antibacterial activity. The celestial god belongs to the cedar tree, the cedar, and the cenotaph. For example, there is a cnidium officinale Makino whose scientific name is Cnidium officinale Makino.

In one aspect, the present invention can effectively combine herbal medicines known to have few side effects on the human body, and extract and concentrate them with ethanol or alcohol to maximize the concentration of the herbal composition. Further, the concentrated liquid of the herbal composition can be dried to provide a powdery composition, which is convenient for taking and carrying.

One example of the preparation of the extract is that the primary processed active ingredient (at least one of the group consisting of ginseng, sea bream, ginseng, ginseng, persimmon, and ginseng) is placed in a high pressure steam boiler, After drying at 65 ° C in a hot air dryer, 1 kg of the processed material was pulverized with a blender, and 10 l of purified water was added thereto. The mixture was stirred for 24 hours at 38 to 42 ° C in hot water, and then immersed at 15 ° C for 1 day . Thereafter, the residue and filtrate are separated by filtration through a filter cloth and centrifugation, and the separated filtrate is concentrated under reduced pressure to 1/10 of the amount of purified water. A concentrated amount of ethanol or a four-fold amount of the alcohol or the alcohol is added dropwise, and the mixture is subjected to hot-air drying to obtain a composition containing the processed active ingredient by using a pesticide.

Compositions for the prophylaxis or treatment of hyperlipidemia may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. The composition for preventing or treating hyperlipidemia may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories and sterilized injection solutions according to a conventional method In one aspect, carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient is usually used. Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, and the like. Such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, and gelatin in addition to the active ingredient. In addition to simple excipients, lubricants such as magnesium stearate talc may also be included. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, syrups and the like. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppositories include witepsol, macrogol, tween 61, laurin, cacao butter, glycerogelatin and the like.

The dosage of the active ingredient disclosed herein may be varied depending on the condition and the weight of the patient, the severity of the disease, the type of the drug, the route of administration and the period of time, and may be selected within a range conventionally used in the art. In one aspect, the daily dose of the active ingredient may be from 0.0001 to 1000 g / kg on a dry weight basis, from 0.001 to 100 g / kg in one aspect, from 0.001 to 10 g / kg in another aspect, 1 g / kg < / RTI > In one aspect, the daily dose may be at least 0.0001 g / kg, at least 0.001 g / kg, at least 0.05 g / kg, at least 0.01 g / kg, or at least 0.05 g / kg. In other aspects, the daily dose may be less than 500 g / kg, less than 100 g / kg, less than 50 g / kg, less than 10 g / kg, less than 1 g / kg, or less than 0.5 g / kg. In one embodiment, the active ingredient may be administered at about 0.086 g / kg / day, and in other embodiments at about 0.143 g / kg / day. The administration may be carried out once a day to five days, or divided into several times a day, and in one aspect, three times a day.

The active ingredients disclosed herein can be administered to mammals such as livestock, humans, and the like in a variety of routes. All modes of administration may be expected and may be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intramural or intracerebroventricular injection.

One aspect of the present invention provides a food or a health functional food for preventing or treating hyperlipidemia. In one aspect, the composition may be a pharmaceutical composition, food and beverage, etc. for the prevention or treatment of hyperlipidemia. For example, various foods, beverages, gums, tea, vitamin complexes, health supplement foods and the like can be used, and they can be used as powder, granule, tablet, capsule or beverage.

In one aspect, the composition of the present invention may be a food or beverage for the purpose of preventing or treating hyperlipemia. In this case, the amount of the active ingredient contained in the food or beverage may generally be from 1 to 5% by weight of the whole food when it is a health food composition, from 0.02 to 10 g based on 100 ml of the health drink composition, 0.3 to 1 g.

In the case of a health drink composition, there is no particular limitation on the liquid ingredient that can be contained in the active ingredient other than the active ingredients disclosed in the present specification, and various flavors or natural carbohydrates such as ordinary beverages may be included as an additional ingredient. Examples of the natural carbohydrate include common saccharides such as disaccharides such as monosaccharide, glucose and fructose, polysaccharides such as maltose and sucrose, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol . The above flavoring agents can be advantageously used as natural flavorings (tau martin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (for example, saccharin, aspartame etc.) The ratio of the natural carbohydrate may be generally about 1 to 20 g per 100 ml of the composition disclosed herein, and about 5 to 12 g per side.

The composition of the present invention can be used in various respects such as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and aging agents (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. The present invention may in one aspect comprise pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination. The proportions of the additives may vary, but are generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.

The composition of the present invention may be a composition for preventing or treating diabetes, which comprises, as an active ingredient, at least one selected from the group consisting of bruvulin, an extract of sea bass, an extract of ginger, a ginseng extract, a ginseng extract, and a ginseng extract. In one aspect, the composition may be a composition for preventing or treating obesity, which comprises at least one selected from the group consisting of bruvulus extract, sea bream extract, interlingua extract, rosemary extract, rosacea extract, and astragalus extract.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are for illustrative purposes only and that the scope of the present invention is not limited by these embodiments.

[Example 1]

10 g of seaweed, 28 g of seaweed, 6 g of glue, 17 g of gaburusil, 17 g of ginseng and 8 g of ganghwag were weighed and finely pulverized and introduced into a circulating pressureless reactor. 670 mL of 30% ethanol was added, and the mixture was stirred under reflux for about 4 hours when the temperature was raised to 80 to 100 ° C. After reflux stirring, the mixture was cooled to room temperature and the extract was filtered. The filtrate was concentrated under reduced pressure. The concentrated extract was dried by hot air to give 27.9 g of powder which was used as a test material for rat.

[Example 2]

10 g of seaweed, 28 g of seaweed, 6 g of glue, 17 g of gaburusil, 17 g of ginseng and 8 g of ganghwag were weighed and finely pulverized and introduced into a circulating pressureless reactor. 95% alcohol (670 mL) was added thereto, and the mixture was stirred under reflux for about 4 hours when the temperature was raised to 80 to 100 ° C. After reflux stirring, the mixture was cooled to room temperature and the extract was filtered. The filtrate was concentrated under reduced pressure. The concentrated extract was dried by hot air to give 23.8 g of powder which was used as a test material for rat.

[Experimental Example 1]

1-1. Preparation of experimental animals

A 5-week-old male Sprague-Dawley (SD) rat was prepared as an experimental animal, and each animal was free-diet in an animal laboratory (22-23 ° C, 55-60% relative humidity) Respectively. Animals were divided into normal (1), negative control (1), experimental group (12) and positive control group (1). Five SD rats were prepared for each group. The normal group means a group of the rats that did not induce hyperlipemia by eating the normal diet and the negative control group refers to the group that did not treat the hyperlipemia induced rats with the hyperlipidemia induced diet and the experimental group, Means a group of rats using the above Example 1 or 2 after hyperlipidemia was induced and the positive control group means a group of rats using simvastatin as a therapeutic agent for hyperlipidemia after hyperlipidemia was induced by ingesting a hyperlipidemia-inducing feed. All animal experiments were conducted with the approval of Jeonnam Oriental Industry Promotion Agency's "Animal Ethics Committee (IACUC)".

1-2. Induce hyperlipemia

Cholesterol-induced hyperlipidemia-induced dietary intake was 1.25%, which was fed for 8 weeks using a hyperlipidemic diet (Uni Faith, D08062402). After 8 weeks, serum triglyceride (TG), total cholesterol (TCHO), high-density lipoprotein (HDL) and low-density lipoprotein (LDL)

1-3. Therapeutic drug administration

After 8 weeks of induction of hyperlipidemia, the groups were divided into negative control group, experimental group (Examples 1 and 2) and positive control group, and each of the candidate drugs for hyperlipidemia treatment was orally administered once per day for 8 weeks at each concentration. Using the powders of Examples 1 and 2, the dose was divided into three groups: 1-fold, 1-fold, 5-fold (or the maximum dose) divided by the weight of each individual, (Sonde, also referred to as postmen, inserted into the body cavity or organs and examined for conditions). In addition, simvastatin (simvastatin) (㈜ bust ^TM information using the House Pharmaceutical) was administered to 3.3mg / kg, calculated as 10 times the amount of human tolerance. The dose of the composition for the rat is shown in Table 1 below. Example 1 refers to an experimental group to which powder powder extracted with 30% ethanol was administered, and Example 2 refers to an experimental group to which powder powder extracted with 95% ethanol was administered.

No. Example 1 Example 2 density that medium The The mg / kg 57 287 1432 1432

1-4. Check the result

In order to confirm the therapeutic efficacy for hyperlipidemia, we examined the change in body weight of the rat for a total of 16 weeks, and confirmed the presence of hyperglycemia in the blood. TG, TCHO, HDL, LDL and hepatic toxicity biochemical markers GOT, GPT, And the value was confirmed. Cardiac puncture was used for blood sampling and only water was supplied 1 day before blood collection. Plasma TG, TCHO, HDL and LDL were measured using a blood biochemical measurement kit .

In the experimental results, the change in the body weight of the first, second, normal, negative, and positive control groups of the hyperlipidemic induction rats was first confirmed. As a result, weight loss was observed in Example 1 as compared with the negative control group, and the decrease was most remarkably observed at 105 ± 3.5 g for 8 weeks in the high concentration group. Example 2 also showed a large weight loss. The results of measuring the weight gain of the lattices of Examples 1 and 2, the normal group, the negative control group, and the positive control group are shown in Table 2.

group Dose (mg / Kg. P.o.) Weight (g) Weight change (g) first later Normal group - 367 ± 9.2 423 ± 6.2 56 ± 8.3 (increase) Negative control group - 593 + - 12.4 652 ± 18.5 59.2 ± 12.8 (increase) Example 1 57 594 9.1 518 ± 12.8 75.4 ± 9.9 (decrease) 287 594 ± 9.7 507 ± 16.9 86.8 ± 8.7 (decrease) 1432 591 ± 10.6 486 ± 9.8 105 ± 3.5 (decrease) Example 2 1432 591 515 76 (decrease) The positive control (simvastatin) 3.3 592 8.3 466 ± 7.8 125.75 +/- 13.6 (decrease)

As shown in FIG. 1, it was confirmed that the content of TG was effectively suppressed as the concentration of Triglyceride (TG) in the blood of Example 1 was elevated. In the high concentration group (1432 mg / kg), 140.4 ± 7.6 mg / dl was found to be similar to that of the normal group. In addition, it was confirmed that Example 2 is smaller than Example 1 but effectively inhibits the increase of blood TG.

As shown in FIG. 2, it was confirmed that the content of TCHO was effectively suppressed at a higher concentration as a result of confirming the effect on blood total TCHO (total cholesterol) content in Example 1 in the hyperlipemia induction lattice. Especially, in the high concentration group (1432 mg / kg), the blood TCHO content was decreased to 76.6 ± 10.1 mg / dl similar to that of the normal group. In Example 2, it was confirmed that TCHO increase in blood was more effectively inhibited than in Example 1 at 71 mg / dl.

As shown in FIG. 3, it was confirmed that the HDL content was effectively restored at a higher concentration as a result of checking the HDL (high-density lipoprotein) content in blood of Example 1 in the hyperlipidemic guinea pig. Especially in the high concentration group (1432 mg / kg), 50.6 ± 6.4 mg / dl was recovered to the normal level. In addition, it was confirmed that Example 2 suppressed the decrease of blood HDL more effectively than Example 1 at 54 mg / dl.

As shown in FIG. 4, it was confirmed that the LDL content in the hyperlipemia induction lattice was effectively suppressed as the concentration of LDL was increased at a higher concentration as a result of checking the blood LDL (low-density lipoprotein) content in Example 1. Especially in the high concentration group (1432 mg / kg), it was confirmed that it was suppressed to the normal group level by 54.1 ± 11.7 mg / dl. Also, it was confirmed that the content of LDL in blood was more effectively inhibited than that of Example 1 at 46.8 mg / dl in Example 2.

As shown in FIG. 5, it was confirmed that the content of GOT was effectively suppressed as the concentration of GOT (Glutamate Oxaloacetate Transaminase) in the hyperlipidemic guinea-pig was increased. Especially in the high concentration group (1432 mg / kg), it decreased to 205.6 ± 20.3 U / l. It was also confirmed that Example 2 effectively inhibited the increase of blood GOT.

As shown in FIG. 6, the GPT content in the hyperlipidemic guinea pig was confirmed to be effectively suppressed as the concentration of GPT increased in the high concentration. Especially in the high concentration group (1432 mg / kg), it decreased to 73.6 ± 6.7 U / l. It was also confirmed that Example 2 effectively suppressed the increase of blood GPT.

As shown in FIG. 7, the effect of γ-GPT (Gamma Glutamyl Transferase) in the blood of Example 1 was confirmed in the hyperlipidemic guinea pig. As a result, it was confirmed that the content of γ-GPT was effectively suppressed at a higher concentration. Especially in the high concentration group (1432 mg / kg), it decreased to 8.8 ± 0.4 U / l. It was also confirmed that Example 2 effectively inhibited the increase of? -GPT in the blood.

As described above, the composition for preventing or treating hyperlipidemia disclosed herein has similar efficacy to the simvastatin substance used in the positive control in the prevention or treatment of hyperlipidemia. In addition, the hepatotoxicity test showed similar liver detoxifying effect to that of simvastatin used in the positive control group.

Hereinafter, formulation examples of compositions for the prevention or treatment of hyperlipemia will be described, but the present invention is not limited thereto.

[Formulation Example 1] Preparation of powders

20 mg of the powder of Example 1 or Example 2, 100 mg of lactose, and 10 mg of talc are mixed and filled in an airtight container to prepare a powder.

[Formulation Example 2] Preparation of tablet

After mixing 10 mg of powder of Example 1 or 2, 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate, tablets are prepared by tableting according to the usual preparation method of tablets.

[Formulation Example 3] Preparation of capsules

10 mg of the powder of Example 1 or 2, 3 mg of crystalline cellulose, 14.8 mg of lactose, and 0.2 mg of magnesium stearate are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

[Formulation Example 4] Preparation of injections

10 mg of the powder of Example 1 or 2, 180 mg of mannitol, 2974 mg of sterilized distilled water for injection, _and 26 mg of Na ₂ HPO ₄ .12H ₂ O are prepared according to the usual injection preparation method with the above ingredient contents (2 ml) per ampoule .

[Formulation Example 5] Preparation of liquid agent

20 mg of the powder of Example 1 or 2, 10 g of isomerized sugar, 5 g of mannitol, and purified water were added to purified water in accordance with the usual preparation method of the liquid preparation and dissolved, and the lemon flavor was added in an appropriate amount. Purified water is added to adjust the total volume to 100 ml. The solution is filled in a brown bottle and sterilized to prepare a liquid preparation.

[Formulation Example 6] Preparation of health food

Compounding ingredient content The powder of Example 1 or 2 1000 mg Vitamin A acetate 70 μg Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 μg Vitamin C 10 mg Biotin 10 μg Nicotinic acid amide 1.7 mg Folic acid 50 μg Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

The composition ratio of the above-mentioned vitamin and mineral mixture is an example of the health food, and the compounding ratio thereof may be arbitrarily changed. The above ingredients are mixed according to a conventional method for producing healthy food, Can be used in the manufacture of a health food composition according to the method.

[Formulation Example 7] Preparation of health drink

Purified water was added to 900 ml of the total of the powder of Example 1 or Example 2, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate and 1 g of taurine, and the above components were mixed according to a conventional manufacturing method, The mixture is stirred and heated at 85 占 폚. The prepared solution is filtered and sterilized in a sterilized 2-liter container. The resulting solution is stored in a refrigerator and then used in the production of the health beverage composition of the present invention. The composition ratio is an embodiment showing a component suitable for a relatively popular beverage. The composition ratio may be arbitrarily modified according to the regional and satisfactory preference such as the demand level, the demanded country, and the intended use.

Claims (10)

A pharmaceutical composition for the prevention or treatment of diabetes or hypertension, which is a complication of hyperlipidemia or hyperlipidemia which contains as an active ingredient an extract of Bacillus sylvestris extract, sea bass extract, intergral extract, rosemary extract, persimmon extract, A pharmaceutical composition for preventing or treating obesity, which comprises as an active ingredient an extract of Bacillus sylvestris, sea cucumber extract, waxy extract, rosemary extract, persimmon extract, and cucumber extract. A food composition for preventing or ameliorating diabetes or hypertension, which is a complication of hyperlipidemia or hyperlipidemia, which comprises as an active ingredient an extract of Bacillus sylvestris extract, sea bass extract, wax extract, rosemary extract, persimmon extract, A food composition for preventing or improving obesity, which comprises as an active ingredient an extract of Bacillus sylvestris, sea cucumber extract, waxy extract, ginseng extract, persimmon extract, and cucurbit extract. 5. The method according to any one of claims 1 to 4,
Wherein the composition comprises the composition according to the present invention in a weight ratio of 1.5 to 2: 2.6 to 3: 0.4 to 1: 1.4 to 2: 0.8 to 1: 0.5 to 1 of the balsuthil extract: seaweed extract: guacamole extract: Gt; 5. The method according to any one of claims 1 to 4,
Wherein the daily dose of the active ingredient is from 0.001 to 1 g / kg, based on dry weight. 5. The method according to any one of claims 1 to 4,
Wherein the active ingredient is in powder form. delete delete 5. The method according to any one of claims 1 to 4,
Wherein the extract is an extract of ethanol or alcohol.

Images